A study published today in The New England Journal of Medicine suggests a link between taking rosiglitazone, used to treat Type 2 diabetes, and an increased risk of stroke and heart attack.
"Diabetes UK does not believe that these findings are cause for alarm," said Matt Hunt, Science Information Manager at Diabetes UK.
"Glitazones are not presently recommended for people who have had, or who are at high risk of having, heart failure. We welcome research into the effects of rosiglitazone - however, this study, by its own admission, has limitations and the results are not conclusive.
"Any suggested link into an increased risk of stroke and death from cardiovascular complications for people taking rosiglitazone needs much more research.
"The Medicines and Healthcare products Regulatory Authority (MHRA) states that rosiglitazone is a safe and effective treatment for those diagnosed with Type 2 diabetes.
"Diabetes UK strongly recommends that people with Type 2 diabetes eat a well-balanced diet and incorporate physical activity into their daily life."